Related Experiment Video For Adipokines
Updated: Oct 15, 2025

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
Published on: October 16, 2010
Breast benign disease and breast cancer risk. Overweight-obesity, biochemical, anthropometry
Luis Aarón Quiroga-Morales1, Daniel Sat-Muñoz2, Brenda Eugenia Martínez-Herrera3
1Instituto Iberoamericano de Ciencias del Deporte y el Movimiento Humano. Guadalajara, Jalisco.
Background:
The immunologic, metabolic and anthropometric disturbances of overweight-obesity phenomena are risk factors to breast cancer (BC), particularly in proliferative benign breast disease women (PBBD).
Objective:
To describe the adipocytokine levels, metabolic alteration and anthropometric characteristics in PBBD and its role as risk estimator to BC in a population with high overweight-obesity prevalence.
Material And Methods:
A cross-sectional study. We realized nutritional diagnosis, anthropometry, and we calculated the waist-height rate (WHR); serum measurement of adipocytokines, insulin and glucose and, HOMA IR determination in 27 PBBD and 27 BC women. We calculated mean, standard deviation, Pearson and Spearman correlation coefficients, Odds Ratio (OR) and confidence intervals through logistic regression as risk estimators of BC; p < 0.05 values were considered significant.
Results:
Mean age in the PBBD group was minor than BC group, the humeral diameter was greater in BC group women. We did not find differences in anthropometry or adipocytokine levels; in both groups, the predominant somatotype was the endo-mesomorphic. We found higher insulin levels in BC group and a higher percentage of women with WHR > 0.5 too. The WHR > 0.5 + age over 50 were considered risk estimators to develop breast cancer in PBBD women group.
Conclusion:
The WHR >0.5 in women with PBBD over 50 years old could be considered an anthropometric risk estimator to develop BC.
Related Concept Videos
Obesity
Cancer Prevention
Some...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Drug Dosing: Obese Patients
Psychoneuroimmunology: Diabetes and Cancer
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

